Ziihera Posts $15.4M in Q2 Sales, FDA Priority Review with Aug 25 PDUFA
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz's newly launched Ziihera generated $15.4M in Q2 sales for biliary tract cancer, showing early commercial traction. The FDA granted Priority Review for a supplemental Biologics License Application in HER2+ first-line gastroesophageal cancer, with a PDUFA date of August 25, 2026 — a near-term catalyst that could significantly expand the drug's label. This follows the strong Q2 earnings beat reported yesterday, where total revenue hit $1.21B, and the separate news this morning that Jazz will withdraw Zepzelca's second-line lung cancer indication. The Ziihera update adds a positive regulatory milestone to the narrative, offsetting the Zepzelca setback.
At the time of this announcement, JAZZ was trading at $256.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $105.00 to $261.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.